title: [Thromboprophylaxis in patients with multiply myeloma who receives chemotherapy with thalidomide].
abstract: Achievements of world practice about development and prophilaxis of tromboembolic events (VTE) in cancer patients. Particular attention is paid to prevention of VTE in patients with multiply myeloma who receive chemotherapy with Thalidomide.
authors.forename: O I
authors.initials: OI
authors.lastname: Novosad
authors.forename: I A
authors.initials: IA
authors.lastname: Kriachok
authors.forename: T V
authors.initials: TV
authors.lastname: Kadnikova
authors.forename: K S
authors.initials: KS
authors.lastname: Filonenko
authors.forename: I B
authors.initials: IB
authors.lastname: Tytorenko
authors.forename: A V
authors.initials: AV
authors.lastname: Martynchyk
authors.forename: O M
authors.initials: OM
authors.lastname: Aleksyk
authors.forename: Iu O
authors.initials: IuO
authors.lastname: Gusachenko
authors.forename: I A
authors.initials: IA
authors.lastname: Filonenko
mesh_terms: D000367:Age Factors; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012307:Risk Factors; D012720:Severity of Illness Index; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D013792:Thalidomide; D014859:Warfarin; D001241:Aspirin